Phase 2 Interstitial Lung Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults who have been clearly diagnosed with Langerhans cell histiocytosis (LCH) that affects multiple body systems, or affects one body system but in more than one location
- People aged between 18 and 70 years old
- People who have not previously received systemic (whole-body) treatment for LCH — those who have only had local radiotherapy or surgery may still be considered
- People with a general health and activity level rated at 2 or below on a standard medical scale (meaning able to care for oneself, though may not be able to do heavy physical work) (confirm with trial site)
- People whose treating doctor considers them suitable for the treatment used in this trial
- People, or their family members, who are able to understand the study and are willing to take part by signing a consent form
Who may not be able to join:
- People whose LCH has spread to the central nervous system (the brain or spinal cord)
- People who have LCH in only one body system with only a single lesion (one affected area)
- People who have had major surgery within the 4 weeks before starting the trial
- People who have received radiotherapy within the 4 weeks before starting the trial
- People who have had a heart attack within the past year
- People with moderate to severe heart failure, or a history of moderate to severe heart failure (classified as NYHA class 3 or 4) (confirm with trial site)
- Women who are pregnant or breastfeeding
- People with significantly reduced liver or kidney function, based on specific blood test results (confirm with trial site for exact values)
- People with low white blood cell or platelet counts, based on specific blood test results (confirm with trial site for exact values)
- People, or their family members, who are not able to understand the purpose and conditions of the study
- People whom the trial doctor considers unsuitable for any other reason
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Xinxin XX Cao, doctor, NCC, CICAMS
Phone: +86-18618315968
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Event-Free Survival (EFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.